Next Article in Journal
Natural Compounds of Salvia L. Genus and Molecular Mechanism of Their Biological Activity
Next Article in Special Issue
Type and Frequency in Use of Nutraceutical and Micronutrient Supplementation for the Management of Polycystic Ovary Syndrome: A Systematic Scoping Review
Previous Article in Journal
Male and Female Mitochondria Respond Differently after Exercising in Acute Hypoxia
Previous Article in Special Issue
Overnight Melatonin Concentration and Sleep Quality Are Associated with the Clinical Features of Polycystic Ovary Syndrome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 12
10.3390/biomedicines11123150
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Elevated Anti-Müllerian Hormone as a Prognostic Factor for Poor Outcomes of In Vitro Fertilization in Women with Polycystic Ovary Syndrome

by
Emídio Vale-Fernandes
1,2,3,*,
Márcia Barreiro
1,2,3,
Carla Leal
1,2,3,
Rosa Zulmira Macedo
4,
António Tomé
4 and
Mariana P. Monteiro
2,3
1
Centre for Medically Assisted Procreation/Public Gamete Bank, Gynaecology Department, Centro Materno-Infantil do Norte Dr. Albino Aroso (CMIN), Centro Hospitalar Universitário de Santo António (CHUdSA), 4050-651 Porto, Portugal
2
UMIB—Unit for Multidisciplinary Research in Biomedicine, ICBAS—School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal
3
ITR—Laboratory for Integrative and Translational Research in Population Health, 4050-313 Porto, Portugal
4
Gynaecology Department, Centro Materno-Infantil do Norte Dr. Albino Aroso (CMIN), Centro Hospitalar Universitário de Santo António (CHUdSA), 4050-651 Porto, Portugal
*
Author to whom correspondence should be addressed.
Biomedicines 2023, 11(12), 3150; https://doi.org/10.3390/biomedicines11123150
Submission received: 22 September 2023 / Revised: 16 November 2023 / Accepted: 21 November 2023 / Published: 27 November 2023
(This article belongs to the Special Issue Advances in Polycystic Ovary Syndrome Research: From Molecular Mechanisms to Therapeutic Strategies)
Browse Figure
Versions Notes

Abstract

Women with polycystic ovary syndrome (PCOS) tend to have elevated anti-Müllerian hormone (AMH) levels, which appear to correlate with disease severity and pregnancy outcomes. This was a retrospective observational study designed to assess the relationship between circulating AMH levels and in vitro fertilization (IVF) outcomes. The study involved 150 women with PCOS who underwent IVF treatments. The women’s IVF cycles were allocated into three subgroups according to AMH levels: ‘low’ (AMH < 3.7 ng/mL; n = 49), ‘middle’ (AMH 3.7–7.4 ng/mL; n = 94), and ‘high’ (AMH > 7.4 ng/mL; n = 56). All pregnancy-related outcomes (positive beta human chorionic gonadotropin (βHCG), clinical pregnancy rate, live birth rate, and cumulative live birth rate) were greater in women’s IVF cycles with ‘low’ AMH when compared to those with ‘middle’ or ‘high’ AMH (p < 0.05). AMH levels below 3.7 ng/mL were found to be associated with lower oocyte immaturity rate and better pregnancy outcomes, although baseline AMH was not shown to have any significant predictive power for live birth and cumulative live birth in the multivariable logistic regression analysis after adjusting for possible confounders nor in the ROC analyses. In summary, the current study lays the groundwork to validate high AMH levels as a poor prognostic factor for pregnancy outcomes after IVF in women with PCOS.
Keywords: in vitro fertilization (IVF); anti-Müllerian hormone (AMH); polycystic ovary syndrome (PCOS); live birth rate; cumulative live birth rate in vitro fertilization (IVF); anti-Müllerian hormone (AMH); polycystic ovary syndrome (PCOS); live birth rate; cumulative live birth rate

Share and Cite

MDPI and ACS Style

Vale-Fernandes, E.; Barreiro, M.; Leal, C.; Macedo, R.Z.; Tomé, A.; Monteiro, M.P. Elevated Anti-Müllerian Hormone as a Prognostic Factor for Poor Outcomes of In Vitro Fertilization in Women with Polycystic Ovary Syndrome. Biomedicines 2023, 11, 3150. https://doi.org/10.3390/biomedicines11123150

AMA Style

Vale-Fernandes E, Barreiro M, Leal C, Macedo RZ, Tomé A, Monteiro MP. Elevated Anti-Müllerian Hormone as a Prognostic Factor for Poor Outcomes of In Vitro Fertilization in Women with Polycystic Ovary Syndrome. Biomedicines. 2023; 11(12):3150. https://doi.org/10.3390/biomedicines11123150

Chicago/Turabian Style

Vale-Fernandes, Emídio, Márcia Barreiro, Carla Leal, Rosa Zulmira Macedo, António Tomé, and Mariana P. Monteiro. 2023. "Elevated Anti-Müllerian Hormone as a Prognostic Factor for Poor Outcomes of In Vitro Fertilization in Women with Polycystic Ovary Syndrome" Biomedicines 11, no. 12: 3150. https://doi.org/10.3390/biomedicines11123150

APA Style

Vale-Fernandes, E., Barreiro, M., Leal, C., Macedo, R. Z., Tomé, A., & Monteiro, M. P. (2023). Elevated Anti-Müllerian Hormone as a Prognostic Factor for Poor Outcomes of In Vitro Fertilization in Women with Polycystic Ovary Syndrome. Biomedicines, 11(12), 3150. https://doi.org/10.3390/biomedicines11123150

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop